CARDIOVASCULAR

CARDIOVASCULAR

Starting with the development of a unique cell-based system for the identification of compounds modulating cardiac rhythm, Fluofarma developed key capacities to support drug discovery in the field of cardiovascular diseases.

IN VITRO CARDIAC ACTIVITY RECORDING

Inositol triphosphate receptor
channel function
H9C2 Cells PF 3.21
hERG channel HEK 293 CV 5.6
hERG trafficking HEK 293 CV 5.10
hNav1.5 channel HEK 293 CV 5.7
hKir2.1 channel HEK 293 CV 5.8
hKir2.1 trafficking HEK 293 CV 5.13
hCav1.2 channel HEK 293 CV 5.9
Cardiac Electrophysiology - Learn More

CARDIOVASCULAR RISK ASSESSMENT

NEW !  Human cardiomyocytes Cor 4U® – iCell® CV 5.14
Cardiovascular Risk Assessment - Learn More

A UNIQUE CARDIAC ARRHYTHMIA CELL-BASED ASSAY

> ES cells differentiated in atrial cardiomyocytes are functionally synced, spontaneously generating heart-beating cycles

> High-throughput monitoring of calcium bursts by FLIPR® Tetra, to identify compounds modulating cardiac rhythm

> A cell-based system suited for screening, drug profiling and cardiotoxicity studies

ADDITIONAL CAPABILITIES